Drummond M., B. O’Brien, G. Stoddart et G. Torrance. Methods for Economic
Evaluation of Health Care Programmes. Oxford Univ Press, 1997.
Sackett, D. Evaluation of health services. NEJM, 296, 1980, 732-737.
Baal, P., D, Meltzer et W. Brouwer. Pharmacoeconomic Guidelines Should
Prescribe Inclusion of Indirect Medical Costs. Pharmacoeconomics, 31, 2013, № 5, 369-374.
Bae, S., S. Lee, E. Bae et S. Jang. Korean Guidelines for Pharmacoecomic
Evaluation. Consensus and Compromise. Pharmacoeconomics, 31, 2013, No. 4, 257-268.
Bobinac, A. et al. Valuing QALY gains by applying a societal perspective.
Health Economics, 22, 2013, 1272-1281.
Eur-Assess Project, WHO Collaborating Center for Knowledge Translation
and Health Technology Assessment in Health Equity, 1994.
Strategy for EU Cooperation on Health Technology Assessment, European
Commission, 2014.
International Network of Agencies for Health Technology Assessment
(INAHTA), www.inahta.org
Oortwijn, W., P. Broos, H. Vondeling et al. Mapping of health technology
assessment in selected countries. Int J TechnolAssess Health Care, 29,
, No. 4, 424-434.
Busse, R., J. Orvain, M. Velasco, et al. Best practice in undertaking and
reporting health technology assessments: Working Group 4 report. Int.
J.Technol.Assess. Health Care,18, 2002, 361-422.
EUnetHTA Work Package 8. EUnetHTA Handbook on Health Technology
Assessment Capacity Building. Barcelona (Spain): Catalan Agency for Health Technology Assessment and Research. Catalan Health Service. Department
of Health Autonomous Government of Catalonia; 2008.
Murphy K. et al. Effective early warning systems for new and emerging health technologies: Developing an evaluation framework and an assessment
of current systems. Int. J. Techol. Assess. Health Care, 23, 2007, 324-330.
Hailey, D. Toward transparency in health technology assessment. A checklist
for HTA reports. Int. J. Techol. Assess. Health Care, 19, 2003, 1-7.
Drummond, M. et al. Key principles for the improved conduct of health
technology assessment for recourse allocation decisions. Int. J. Techol.
Assess. Health Care, 24, 2008, 244-258.
Наредба за условията, правилата и реда за регулиране и регистриране
на цените на лекарствените продукти, ПМС № 97 от 19 април 2013,
ДВ, брой 40 от 30 април 2013 г.
Проследяване на лекарствената безопасност. Закон за лекарствените
продукти в хуманната медицина, ДВ, брой 102 от 12 декември 2012 г.
Закон за здравното осигуряване, ДВ брой 70 от 19 юни 1998 г.
Национална здравна стратегия 2014-2020. МЗ, www.invester.bg
Al, M. Cost-effectiveness acceptability curves revisited. Pharmacoeconomics,
, 2013, № 2, 93-100.
Husereau, D., M. Drummond, S. Petrou, et al. Consolidated Health Economic
Evaluation Reporting Standards (CHEERS) statement. Int. J. Technol. Assess. Health Care, 29, 2013, № 2, 117-122.
Наредба за условията, правилата и реда за регулиране и регистриране
на цените на лекарствените продукти, ПМС № 97/19.4.2013, ДВ 40 от 30 април 2013.
Оценъчна таблица на показателите по чл. 30, Приложение № 5 към
Наредба за условията, правилата и реда за регулиране и регистриране на цените на лекарствените продукти, ДВ 40 от 30 април 2013.
Drummond M. Т. Schwartz, B. Jönsson et al. Key principles for the improved
conduct of health technology assessments for resource allocation decisions. Int. J.Technol. Assess. Health Care, 24, 2008, № 2, 244-258.
Turner, L. et al. Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical
journals? A Cochrane review, Syst. Rev., 1, 2012, 60.
McGrhan, W. et al. The ISPORT Good practices for quality improvement
of Cost Effectiveness Research Task Force report. Value Health, 12, 2009,
№ 8, 1086-1099.
Siegel, J., M. C. Weinstein, L. B. Russell et al. Recommendations for reporting
cost-effectiveness analyses. Panel on Cost effectiveness in Health and Medicine. JAMA, 276, 1996, № 16, 1339-1341.
Moher, D., K. F. Schulz, I. Simera, et al. Guidance for developers of health
research reporting guidelines. PLoS Med., 7, 2010, № 2, 102-117.
Moher D., L. Weeks, M. Ocampo et al. Describing reporting guidelines for health research: a systematic review. J. Clin. Epi., 64, 2011, 7, 718-42.
Goetghebeur, M., M. Wagner, H. Khoury et al. Evidence and Value: Impact
on DEcisionMaking – the EVIDEM framework and potential applications.
BMC Health Serv. Rev., 8, 2008, 270-283.
Nuijten, M. M. H. Pronk, M. J. Brorens, et al. Reporting format for economic
evaluation. Part II: Focus on modelling studies. Pharmacoeconomics, 14, 1998, № 3, 259-258.
Rennie, D. et H. Luft. Pharmacoeconomic analyses: making them transparent,
making them credible. JAMA, 283, 2000, № 16, 2158-2160.
Drummond, M., M. Sculpher, G. Torrance et al. Methods the Economic
Evaluation of Health Care Programmes, 3rd ed., Oxford Univ Press, 2005.
Economic analysis of health care technology. A report on principles. Task
Force on Principles for Economic Analysis of Health Care Technology.
Ann. Intern. Med., 123, 1995, № 1, 61-70.
Drummond, M., A. Manca, et M. Sculpher. Increasing the generalizability
of economic evaluations: recommendations for the design, analysis, and reporting
of studies. Int. J. Technol. Assess. Health care, 21, 2005, 2, 165-71.
Ramsey, S., R. Willke, A. Briggs, et al. Good research practices for costeffectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health, 8, 2005, № 5, 521-533.
Gold, M. Cost-effectiveness in Health and Medicine. Oxford University Press, 1996.
Vintzileos, A. et T. Beazoglou. Desing, execution, interpretation and reporting
of economic evaluation studies in obstetrics. Am. J. Obstet Gynecol., 191, 2004, 1070-1076.
Petrou, S. et A. Gray. Economic evaluation using decision analytical modeling: design, conduct, analysis and reporting. BMJ, 342, 2011, d1766.
Drummond, M. et T. Jefferson. Guidelines for authors and peer reviewers
of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ, 313, 1996, № 7052, 275-283.
Neumann, P. P. W. Stone, R. H. Chapman et al. The quality of reporting in
published cost-utility analyses 1976-1997. Ann. Intern. Med., 132, 2000, № 12, 964-978.
Rosen, A., D. Greenberg, P. W. Stone et al. Quality of abstracts of papers
reporting original cost-effectiveness analyses. Med. Decis. Makinh, 25,
, № 4, 424-428.
Petrou, S. et A. Gray. Economic evaluation alongside randomized controlled
trials: desing, conduct, analysis and reporting. BMJ, 342, 2011, d1548.
Yaish, P., A. Gazit, C. Gilon et A. Levitzki. Blocking of EGF-dependent
cell proliferation by EGF receptor kinase inhibitors. Science, 1988; 242(4880):933-935.
Posner I., M. Engel, A. Gazit еt al. Kinetics of inhibition by tyrphostins of
the tyrosine kinase activity of the epidermal growth factor receptor and
analysis by a new computer program. Mol Pharmacol. 1994; 45(4):673-83.
